Cancer Research

Bavarian Nordic Receives US$50 Million Advance Payment From HHS For Fulfilling Contract Milestones

WASHINGTON, D.C., October 9 /PRNewswire/-- Bavarian Nordic, the Danish-based international biopharmaceutical company, has received permission from the Department of Health and Human Services (HHS) to invoice an advance payment of US$50 million as allowed ...

Article - Anna Ohlden - Oct 9 2007 - 10:12am

Gates Foundation Launches US$100 Million Initiative To SpurInnovation In Global Health Research

CAPE TOWN, South Africa, October 9 /PRNewswire/--- Fast-Track Grants Initiative to Support Hundreds of Research Projects Involving Scientists Around the World The Bill & Melinda Gates Foundation announced today that it is committing US$100 million ove ...

Article - Anna Ohlden - Oct 9 2007 - 1:39pm

Data From MedImmune Infectious Disease Clinical Programs Presented At European Society For Paediatric Research Annual Meeting

PRAGUE, Czech Republic, October 9 /PRNewswire/-- MedImmune today announced that six abstracts have been presented at the 2007 European Society for Paediatric Research (ESPR) Annual Meeting demonstrating the company's commitment to advancing the scien ...

Article - Anna Ohlden - Oct 9 2007 - 2:04pm

EpiCept Corporation Announces Pricing Of Public Offering

TARRYTOWN, New York, October 10 /PRNewswire/-- EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) announced today the pricing of a public offering of approximately 4.26 million shares of its common stock at US$1.88 per share and five-year warrants ...

Article - Anna Ohlden - Oct 10 2007 - 9:57am

Cancer Treatment: Drugs During Adjuvant Chemotherapy May Not Work

Women under the age of forty with breast cancer who are given drugs in addition to lumpectomies or radiotherapy, known as adjuvant chemotherapy, may not be benefiting from these drugs. This is especially true if their tumors respond to changing levels of h ...

Article - News Staff - Oct 10 2007 - 9:55pm

Sir Walter Bodmer Joins Oxford Genome Sciences Scientific Advisory Board

OXFORD, England, October 11 /PRNewswire/-- Oxford Genome Sciences (UK) Ltd "OGeS" announces today that it has further strengthened its Scientific Advisory Board (SAB) with the appointment of Sir Walter Bodmer, currently Head of the Cancer and Im ...

Article - Anna Ohlden - Oct 11 2007 - 5:31am

Prof. Michel Klein Becomes Chief Scientific Officer At AMVAC

...

Article - Anna Ohlden - Oct 11 2007 - 8:33am

Genzyme And Bayer Schering Pharma AG, Germany To Present New Data On Alemtuzumab In Multiple Sclerosis At ECTRIMS

CAMBRIDGE, Massachusetts and BERLIN, October 11 /PRNewswire/-- Genzyme Corporation and Bayer Schering Pharma AG, Germany announce that important, new clinical data will be presented this weekend from two studies regarding alemtuzumab use in patients with ...

Article - Anna Ohlden - Oct 11 2007 - 3:06pm

No 'Love, Actually' For People With RA- Research Shows The Real Price Of Rheumatoid Arthritis

LONDON, October 12 /PRNewswire/-- The story? The painful inflammatory disease rheumatoid arthritis costs society GBP1.3 billion a year(1). But research published to mark World Arthritis Day has shown that the real price paid by sufferers is far higher. Ne ...

Article - Anna Ohlden - Oct 11 2007 - 7:02pm

Resverlogix Is Presenting At IAS HDL Workshop

CALGARY, Canada, October 12 /PRNewswire/--- Novel ApoA-I/HDL Raising Drug, RVX-208, to be Featured in Oral Presentation Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tommorrow it is making an oral presentation highlight ...

Article - Anna Ohlden - Oct 12 2007 - 12:43am